Loading…
Loading…
ARGX does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for ARGX and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for ARGX and 80,000+ other tickers.
See exactly how ARGX's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for ARGX and 80,000+ other tickers.
argenx SE, a biotechnology company established in Amsterdam, the Netherlands, in 2008, is dedicated to developing innovative therapies primarily for autoimmune diseases. The company's operations span across key global markets, including the United States, Japan, Europe, the Middle East, Africa, and China. Its leading investigational therapy is efgartigimod, which is being developed to address a broad range of conditions. These include generalized myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous…
Product net sales reached $1.7 billion, growing 54% year over year. Operating profit reached $486 million with a 28% operating margin.
argenx SE ( ARGX ) Q3 2026 Earnings Call October 22, 2026 8:30 AM EDT Company Participants Beth DelGiacco Karen Massey - CEO & Executive Director Karl Gubitz - Chief Financial Officer Sandrine Piret-Gerard - Chief Commercialization Officer Luc Truyen - Chief Medical Officer Conference Call Participants Daniel Giraldo Perez - BofA Securities, Research Division Derek Archila - Wells Fargo Securities, LLC, Research Division Victor Floch - BNP Paribas, Research Division Gavin Clark-Gartner - Evercore ISI Institutional Equities, Research Division Akash Tewari - Jefferies LLC, Research Division Yaron Werber - TD Cowen, Research Division Yatin Suneja - Guggenheim Securities, LLC, Research Division Alexander Thompson - Stifel, Nicolaus & Company, Incorporated, Research Division Danielle Brill Bongero - Truist Securities, Inc., Research Division Myles Minter - William Blair & Company L.L.C., Research Division Rajan Sharma - Goldman Sachs Group, Inc., Research Division Jing Deng Sean Laaman - Morgan Stanley, Research Division Sophia Graeff Buhl Nielsen - JPMorgan Chase & Co, Research Division Luca Issi - RBC Capital Markets, Research Division Douglas Tsao - H.C.
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Harmony Biosciences Holdings, Inc. (HRMY) and argenex SE (ARGX). But which of these two stocks offers value investors a better bang for their buck right now?
argenex NASDAQ: ARGX reported third-quarter 2026 product net sales of $1.7 billion, up 54% from a year earlier and 13% sequentially, as patient growth in generalized myasthenia gravis, or MG, and chronic inflammatory demyelinating polyneuropathy, or CIDP, continued to support demand for VYVGART.